Clinical Trials Browser

Borderline Resectable Pancreatic Cancer × folfirinox × Clear all

NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Phase 2 Unknown

Gastrointestinal

Borderline Resectable Pancreatic Cancer